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Abstract
Cardiovascular diseases (CVD) continue to be the leading cause of death in the world 
despite recent therapeutic advances. Although many CVDs remain incurable, enormous 
efforts have been placed in harnessing angiogenesis as therapeutics for these diseases. 
Epigenetics, the modification of gene expression post-transcriptionally and post-trans-
lationally, are important in regulating many biological processes. One of the main 
post-translational epigenetic modifications, modification of chromatin structure by the 
acetylation of histone tails within the chromatin by either histone deacetylases (HDACs) 
or histone acetyltransferases (HATs), is important in modulating gene transcription and 
has emerged as an important regulatory player from pathogenesis to therapeutics in 
CVDs. Particularly, HDACs, which are largely involved in promoting chromatin compac-
tion and hence inhibitions of gene transcription, have been implicated in the pathogenic 
signalling underlying many aspects of CVDs. Recently, histone modifications have been 
demonstrated to play important roles in the angiogenesis process. Pharmacological inhi-
bitions of HDACs have displayed promising therapeutic potentials in several pre-clinical 
models of CVDs where angiogenesis is of paramount importance. There are many evi-
dences proving that pro- and anti-angiogenic therapies—and the impact of epigenetics in 
these processes—can help to artificially reconstruct the vasculature in patients with car-
diovascular diseases. Conversely, utilising knowledge of HDACs in angiogenesis might 
help to develop anti-angiogenic therapies in tackling diseases that are characterised with 
excessive pathological angiogenesis, including cancer and age-related macular degen-
eration. Understanding the molecular mechanisms underlying HDACs in modulating 
angiogenesis will undoubtedly benefit future therapeutics development. This chapter 
focuses on the emerging role of HDACs in angiogenesis and discuss their potentials and 
challenges in utilising HDAC inhibitors as therapeutics in several major cardiovascular 
diseases.
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1. Introduction
Cardiovascular diseases (CVDs) are a worldwide epidemic that have serious implication in 
public health and constitute a huge amount of healthcare expenditure. Although there are a 
number of preventable controllable risk factors, such as hypertension, hypercholesterolemia, 
smoking, obesity, lack of physical activity and diabetes, and others such as age, gender and 
family history are unmodifiable [1]. Progress in genetic sequencing has allowed the identifi-
cation of numerous genetic variants associated with specific CVDs [2], but their mechanisms 
remain unclear. The last few years of research have been a key in understanding how epi-
genetic mechanisms such as histone modifications are involved in the occurrence and pro-
gression of CVDs including atherosclerosis, heart failure, myocardial infarction and cardiac 
hypertrophy.
Epigenetics represent a phenomenon of altered heritable gene expression without changes 
to the underlying DNA sequences. The epigenetic alterations can be affected by exogenous 
stimuli such as diabetes milieu, diets and smoking, while at other times these alterations can 
subsequently trigger disease initiation [3]. Thus, the impact of epigenetics in CVD is now 
emerging as an important regulatory key player at different levels from pathophysiology 
to therapeutics. For instance, histone alterations have been implicated in ECs response to 
hypoxia and shear stress, in angiogenesis and in endogenous recovery following myocardial 
infarction (MI) [4]. On the other hand, HDAC inhibitors (HDACi) have been investigated for 
potential protective effects in heart muscles during acute MI [4, 5].
Tissue repair is one of the main therapeutic challenges facing the scientific community. There 
are various approaches in improving tissue recovery depending on the pathological condi-
tions, but most of these conditions are initiated by local ischaemia and require a rich net-
work of blood supply for tissue regeneration. Hence, angiogenesis plays a vital part in tissue 
regeneration in the treatment of CVDs. At present, the promising potentials of angiogenesis 
therapies are in full swing.
2. Vascular system
2.1. Cardiovascular system
The cardiovascular system consists of three main components: heart, blood vessels (arter-
ies, veins and capillaries) and blood. There are three types of anatomically and function-
ally distinct blood vessels: arteries, veins and capillaries. The arteries are primarily involved 
in the delivery of oxygenated blood and nutrients from the heart to target organs and tis-
sues. They have thicker and more elastic vessel walls to complement the higher blood pres-
sure for blood delivery from the heart. The veins carry deoxygenated blood, together with 
waste products and other factors secreted by the tissues back to the heart. They tend to have 
larger luminal areas and thinner vessel walls compared to the arteries, and have valves to 
complement the pressure changes. Connecting these two vessel systems are the capillar-
ies that allow the direct exchanges of oxygen and nutrients with carbon dioxide and waste 
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products between the  target tissues and the blood. The walls of all vessels are generally 
composed of three layers: the tunica intima, tunica media and tunica adventitia. The inner-
most layer is formed by the tunica intima, which is made up of a single layer of ECs and 
connective tissues, both of which overlie the internal elastic lamina. The tunica intima has 
an important function as a selective permeable barrier between the extravascular space, the 
vascular wall and the blood. The tunica media forms the muscular element of blood vessels 
that resides between the tunica intima and the tunica adventitia, and comprises circumfer-
entially arranged smooth muscle cells (SMCs) enclosed by a layer of external elastic lamina. 
They provide supports to the vessels and regulate blood flow and pressure via controlling 
the luminal diameter. The outermost layer, the tunica adventitia, is made up of connective 
tissues and matrix-secreting fibroblasts. It is critical to maintaining vascular structure and 
helps to anchor vessels in place to fit into the surrounding tissues. Capillaries constitute non-
muscular vessels and are only made up of an internal elastic lamina covered by a monolayer 
of ECs, and provide a huge surface area for exchanges of vital blood components and factors 
between vessels and tissues.
2.2. Endothelial cells and their impairments in CVDs
Vascular endothelial cells (ECs) have a crucial and diverse role, arraying the innermost layer 
of the entire circulatory system. They act as the semi-selective and non-adherent barrier 
between the lumen of the vessels and the underlying tissues, regulating tissue perfusion and 
movement of inflammatory cells between them [6]. They are involved in regulating vascular 
permeability, blood flow, vascular tone and blood coagulation and are essentially involved 
in vascular remodelling in responses to diverse physiological and pathological stimuli. 
Physiologically, ECs exert anti-coagulant and anti-thrombotic effects through the secretion 
of anti-coagulant factors such as prostacyclin, nitric oxide (NO) and prostaglandin-E2, and inhibit inflammatory cell adhesion in order to maintain vascular homeostasis [7]. Under path-
ological states, ECs are activated by vascular insults or pro-inflammatory cytokines, leading 
to increased permeability, encouraging extravasations of immune cells, which are followed 
by a series of pathological events leading to eventual vascular remodelling [7]. Decreased 
EC secretion of the potent vasodilator NO as a result of repressed activity of endothelial NO 
synthase (eNOS) also contributes to the circus of vascular pathogenesis [8]. These endothelial 
dysfunctions, whether environmental, genetic or a combination of both, critically contribute 
to the pathophysiology of many CVDs such as hypertension and atherosclerosis, and repre-
sent the discernible therapeutic targets for drug development [9].
3. Angiogenesis
There are three main processes that contribute to the formation of new blood vessels that are 
termed globally as neovascularisation:
– Vasculogenesis is defined as the de novo formation of vascular structures by the migration 
of stem cells to the site of vascularisation and differentiation into ECs. Although it was 
originally thought to be exclusive to embryonic development, it is now widely accepted 
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that the process can also take place in adults, which opens up  a new avenue for clinical 
applications [10].
– Angiogenesis is the formation of new blood vessels by sprouting from pre-existing small 
vessels in embryonic and adult tissue or by intravascular subdivision process [11]. This 
process is believed to be induced by angiogenic factors including fibroblast growth factor 
(FGF) and vascular endothelial growth factor (VEGF).
– Arteriogenesis results from the hypertrophy and luminal distention of pre-existing collat-
eral vessels, which involves specific remodelling of existing nascent EC tubules for greater 
size, elasticity and stability through the recruitment of and enclosure by SMCs and peri-
cytes that secrete specific extracellular matrices. Therefore, these vessels have fully devel-
oped tunica media and tunica adventitia [11].
Angiogenesis is a very complex process that can be simplified into three categories: mechani-
cal, chemical and molecular factors (see Ref. [12] for a more extensive review).
– Cellular factors: There are many molecules that can modulate angiogenesis. The most 
essential angiogenic growth factors are as follows: FGF, VEGF, placenta growth factor, 
angiopoietin-1 and angiopoietin-2. Several pathological conditions can also initiate angio-
genesis. For example, hypoglycaemia increases the expression of critical angiogenic induc-
tor VEGF [13]. It has also been extensively demonstrated that the presence of inflammatory 
cells, like macrophages and neutrophils, is sufficient to induce angiogenesis [14].
– Environmental factors: Angiogenesis can be induced by hypoxia and through increased EC 
production of NO. Hypoxia stimulates the release of several angiogenic factors including 
platelet-derived growth factor and FGF-1 and FGF-2 by macrophages. Hypoxia also upreg-
ulates VEGF production, which is known to induce the production and secretion of NO 
from ECs, while eNOS production is amplified during VEGF-induced angiogenesis [15].
– Mechanical factors: There are two main factors: haemodynamic and shear stress. 
Haemodynamic changes trigger an augmentation of blood flow and might therefore stim-
ulate vascular sprouting, maintain patency of the newly formed collateral vessels and pro-
vide blood flow to the ischemic area [16]. Shear stress has an important influence on the 
development of collateral vessel networks in the ischaemic tissues.
4. Epigenetics
The nucleosome is the fundamental subunit of chromatin in eukaryotes. Each nucleosome 
consists of a 146-bp DNA segment wrapped around an octamer of core histone proteins that 
includes two molecules of histones H2A, H2B, H3 and H4 associated with a single copy of 
histone H1. Epigenetics is defined as the study of stable alterations of gene expression without 
alterations of DNA itself. These alterations include the post-translational addition or removal 
of methyl groups to DNA as well as methyl, acetyl, sumoyl and phospho groups to histones 
and other kind of proteins. These changes participate in remodelling chromatin and modifying 
its accessibility to transcription factors and cofactors [17]. Epigenetic control is one of the main 
Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy152
regulatory systems contributing to phenotypic differences between cell types in multicellular 
organisms. Epigenetic changes may explain why subjects with similar genetic backgrounds 
and risk factors for particular diseases can differ greatly in clinical manifestation and therapeu-
tic response [18]. It has been reported that epigenetic mechanisms play a critical role in regu-
lating endothelial gene expression [19]. Among these epigenetic changes are the methylation 
of DNA, RNA-based mechanisms and the posttranslational modification of histone proteins.
DNA methylation
The methylation of DNA involves the covalent modification of the 5-position of cytosine 
to define the ‘fifth base of DNA’, 5-methyl-cytosine [20]. In mammals, DNA methylation is 
almost exclusively restricted to CpG dinucleotides. DNA methylation is catalysed by DNA 
methyltransferases and regulates biological processes underlying CVD, such as atherosclero-
sis, inflammation, hypertension, and diabetes [21].
RNA-based mechanisms
1. miRNA therapeutics
 MicroRNAs (miRNA or miR) are short (20–22 nucleotides) non-coding RNAs modulat-
ing gene expression further by down-regulating the translation of target mRNAs through 
the inhibition of post-transcriptional events, through transcript degradation or through 
direct translational repression.
2. Long non-coding RNAs (lncRNAs)
 Long non-coding RNAs (lncRNAs) are gaining more prominence as regulators of gene 
expression. The central role that lncRNAs play in heart development is only slowly being 
recognised [18]. Besides, understanding the function of these molecules in CVD is even 
further away.
Histone modification
It is well established that histone residues can undergo a wide array of modifications. At least 
eight different types of modification have been characterised with a range of enzymes identi-
fied for each: acetylation, methylation, phosphorylation, ubiquitination, sumoylation, ADP-
ribosylation, deimination, and proline isomerisation (Table 1).
Histone methylation is modulated by two enzymes: histone methyltransferases and histone 
demethylases. The acetylation status of histone is fine-tuned by histone acetyltransferases 
(HATs) and HDACs. HDACs are enzymes that remove acetyl groups from histone lysine 
residues thereby increasing their negative charges, which lead to chromatin condensation and 
gene repression [17].
4.1. The HDAC family
Deacetylation of histones in nucleosomes induces chromatin compaction, which represses 
transcription by preventing the binding of transcription factors and other components of the 
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transcriptional machinery onto the gene promoter and enhancer regions. HDACs are enzymes 
that remove acetyl groups from hyperacetylated histones, and modification by HDACs leads 
to a closed chromatin structure and suppression of genes. HDACs are recruited to gene pro-
moters by DNA-binding proteins that recognise certain DNA sequences and in this way pro-
vide specific modulation on gene expression.
There are 18 characterised members of the HDAC family in mammals, which can be grouped 
into four classes depending on their functional similarities and their homology with yeast 
HDACs. The class I and class II HDACs are considered as the ‘classical’ HDACs [23].
Class I HDACs comprise nuclear, ubiquitously expressed HDACs 1, 2, 3, and 8. HDAC1, 2, and 
8 reside nearly exclusively in the nucleus. HDAC3 is found to shuttle between nucleus and cyto-
plasm. Because these are ubiquitously expressed and involved in cell proliferation and survival, 
aberrations in their gene expression have been implicated in a wide range of cancers [24, 25].
Class II HDACs shuttle between the cytoplasm and the nucleus depending on specific cellular 
signals; they share a tissue-specific expression pattern and are divided into two  subgroups: 
Modification type Amino acid modification Examples of modifying 
enzymes
Role
Acetylation Lysine Histone acetyl transferases 
(HATs)
Transcription Repair 
Histone deacetylases 
(HDACs)
Replication Condensation
Methylation Lysine Lysine methyltransferases Transcription
Lysine demethylases Repair
Arginine Arginine methyltransferases Transcription
Arginine demethylases
Phosphorylation Serine Serine/threonine kinases Transcription
Threonine Dephosphorylated by 
phosphatases
Repair Condensation
Ubiquitination Lysine Ubiquinases (ubiquitin 
ligases)
Transcription
Deubiquinating enzymes Repair
SUMOylation Lysine Small ubiquitin-like modifier 
(SUMO) 
Transcription
De-SUMOylating enzymes: 
sentrin-specific proteases
ADP ribosylation Glutamate ADP-ribosyltransferases Transcription
Deimination Arginine (to Citrulline) Peptidylarginine deiminases Transcription
Proline isomerisation Proline Proline isomerases Transcription
Table 1. Types of histone modifications and the enzymes responsible (modified from Ref. [22]).
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class IIa (HDACs 4, 5, 7, and 9) and class IIb (HDACs 6 and 10). Class IIa HDACs distinguish 
themselves with their extended N-terminal regulatory domain, whereas class IIb HDACs con-
tain two catalytic domains. Class IIa HDACs appear to have tissue-specific roles and can shut-
tle between the cytosol and the nucleus. In fact, the phosphorylation status is a critical event to 
determine their localisation in the nucleus or cytoplasm and the ability to act as transcriptional 
co-repressors in the nuclear region. Conversely, class IIb is mostly found in the cytosol [26].
Class III HDACs regroup the ubiquitously expressed silent information regulator 2 (Sir2) 
family of nicotinamide adenine dinucleotide (NAD+)-dependent HDACs (SIRT1–7), which 
share structural and functional similarities with the yeast Sir2 protein. Interestingly, these 
have a critical role in a wide range of cellular processes such as ageing, transcription, cell sur-
vival, DNA repair, apoptosis, and inflammation. Sirtuins appear to have contradictory roles 
in disease. On the one hand, they control many vital functions involved in cellular protection, 
while on the other hand, they are also involved in several disease pathologies such as meta-
bolic diseases, neurodegenerative disorders, and cancer [27].
Finally, class IV HDAC is the newly discovered HDAC11. HDAC11 is most closely related to 
class I HDACs. However, since the overall sequence similarities are low, it cannot be grouped 
into any of the three existing classes. HDAC11 is primarily expressed in heart, smooth muscle, 
kidney, and brain tissues.
Recent reports suggest that HDACs can deacetylate non-histone proteins as additional func-
tions of HDACs (Figure 1). The roles of HDACs in cancer and neurological diseases have 
Figure 1. Schematic illustration of HDACi downstream effects. Inhibition of HDACs by HDACi induces acetylation of 
histone proteins as well as non-histone proteins, which leads to the alteration in various physiological and pathological 
processes (modified from Refs. [28–30]).
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been extensively examined. However, the functions of HDACs in cardiovascular diseases and 
arteriosclerosis are less explored [23].
4.2. HDAC inhibitors
There has been a breakthrough in the development of HDACi. These HDACi induce acety-
lation of histone proteins, as well as non-histone proteins, which leads to the alteration and 
regulation of biological events including angiogenesis, apoptosis/autophagy, cell cycle, fibro-
genesis, immune response, inflammation, and metabolism (Figure 1). As a result, HDAC 
inhibitor-based therapies have gained substantial attention as treatments for cardiovascular 
diseases and cancer.
In the following sections, we will describe the different exerted functions of HDACi in differ-
ent physiological and pathological conditions.
5. The role of HDACs in angiogenesis: HDAC-regulated ECs  
functions in vitro
During development of the embryo and the physiological repairs of any tissue damages, the 
formation of new blood vessels plays a major role. The process can either involve vasculogen-
esis where ECs may be derived from the differentiation of different kinds of stem cells such 
as embryonic stem (ES) cells, while angiogenesis requires the proliferation, migration, and 
sprouting of ECs. Some of these new blood vessel formations are normal and beneficial as 
seen in wound healing after trauma and ischemic tissue restoration. However, pathological 
neovascularisation leads to many diseases such as diabetic retinopathy, tumour, and inflam-
mation. Over the past decade, investigations into the role of HDACs in the regulations of 
these processes have gained some tractions. We have previously shown that the stabilisation 
of the class I HDAC3 plays an essential role in VEGF receptor 2 (VEGFR2)-mediated endo-
thelial differentiation of mouse ES cells (mESC)-derived Sca-1+ progenitors [31], while these 
events can also signal through VEGR2-HDAC3 stabilisation in a ligand-independent manner 
through exposure to laminar shear flow [32]. These derived EC-like cells display increased 
angiogenic potential by significantly enhancing re-endothelialisation with the host vessels 
upon their transplantation into a mouse wire injury model and substantially attenuated the 
injury-induced neointimal hyperplasia [32]. In addition, HDAC3 is also essential for the sur-
vival of ECs under atherogenic disturbed flow, and knock-down of HDAC3 increases neo-
intima formation in the atheroprone ApoE−/− mice [33]. Overall, these show HDAC3 plays a 
role in the angiogenic processes.
Angiogenic activation of ECs to migrate and to form sprouts is associated with characteristic 
changes in gene expression profiles [34], which can be modulated by the inhibition of HDAC. 
HDAC inhibitions by pan-HDAC inhibitors such as suberoylanilide hydroxamic acid (SAHA) 
and trichostatin A (TSA) can suppress VEGF-induced capillary-like structures formation in 
human umbilical vein endothelial cells (HUVEC) by suppressing angiogenic factors such as 
hypoxia-inducible factor 1 alpha (HIF-1α), VEGF, and eNOS while both HDACi also prevent 
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the sprouting of capillaries from rat aorta [35]. Discrepant reports exist however, as another 
study has shown that treatment with SAHA or a more class I selective inhibitor valporic acid 
(VPA) in combination with VEGF indeed resulted in enhanced EC sprouting [36]. These dis-
crepancies could be due to the contrasting roles that other HDACs within the same class and/
or from the other classes might play in regulating angiogenesis.
In fact, it is common that completely opposite role has been reported for other HDACs in the 
regulation of angiogenesis. HDAC4, a class IIa HDAC, was reported to negatively regulate 
angiogenesis by reducing VEGF expression [37], while others have reported HDAC4 induces 
angiogenesis through an increase in stability of HIF-1γ [38]. In addition, Zhang et al. showed 
that HDAC4 inhibition facilitated c-kit+ cardiac stem cells (CSCs) into the differentiation of 
cardiac lineage commitments with EC potential in vitro [4].
Diverse role has also been reported in another class IIa HDAC HDAC5. On the one hand, 
HDAC5 has been shown to repress KLF2 an important regulator of EC homeostasis that is 
normally expressed in the laminar flow-exposed (therefore atheroprotective) segments of the 
vessels, which results in repressed eNOS expression in ECs [39]. This anti-angiogenic role of 
HDAC5 was validated by siRNA-mediated knock-down of HDAC5 that promoted migration 
and sprouting of ECs [40]. Conversely, phosphorylation-dependent nuclear exports of HDAC5 
[40] and HDAC7 [41], thereby the de-repression of target genes, are crucial for the expression of 
VEGF or metalloproteinase-10 in ECs that lead to increased angiogenesis. Moreover, blockade of 
HDAC7 phosphorylation with a signal-resistant HDAC7 mutant represses EC proliferation and 
migration in response to VEGF, confirming the important role of both class IIa HDACs plays in 
VEGF-mediated angiogenesis [42]. In addition, HDAC7 has also been identified as a key modu-
lator of EC migration at least in part by regulating PDGF-B/PDGF-beta gene expression [43].
Evidence from our laboratory demonstrated that mouse HDAC7 undergoes alternative trans-
lation during mouse ESCs differentiation, resulting in the production of a 7-amino acid pep-
tide (Data not publish yet). This peptide was shown to enhance mouse vascular progenitor 
cell migration and VEGF-induced differentiation towards the EC lineage in vitro. Overall, 
HDAC7 appears to be pro-angiogenic, while the mediating role of HDAC5 in angiogenesis 
could be largely dependent on its translocation within the nucleus.
There is a limited research into the role of class IIb HDAC in angiogenesis, but neverthe-
less HDAC6 can be classified as a pro-angiogenic factor as it induces cell migration by the 
deacetylation of cytoskeletal proteins [44, 45]. Class III HDAC SIRT1 is also highly expressed 
in the vasculature during blood vessel growth where it controls the angiogenic activity of 
ECs. Loss of SIRT1 function leads to blockage of sprouting angiogenesis [46]. Furthermore, 
SIRT1 associates with and deacetylates transcription factor Foxo1 and hence restricts its anti-
angiogenic activity [46].
6. The role of HDAC in therapeutic angiogenesis
Different strategies for therapeutic angiogenesis, including the direct delivery of angiogenic 
growth factors and the delivery of cells to ischemic tissues, have been developed. Moreover, 
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there is a recent progress on therapeutic angiogenesis by utilising polymeric biomaterials, 
combined with stem cell and gene therapy as well as stimulation of endogenous stem cell 
homing (see Ref. [47] for a more comprehensive review).
Owing to the disadvantage of invasiveness, limited drug diffusion, and lack of selectivity 
towards targeted tissues, treatments with traditional drugs and surgery are becoming less 
commonly used [48]. An emerging technique, ultrasound-targeted microbubble destruction 
(UTMD), has been proposed as a non-invasive and specific targeting approach in angiogenic 
therapy of CVDs. UTMD might create a series of biological effects, including improving 
recovery of local tissue damages, improving transient membrane permeability, and extrava-
sation to facilitate the entering of targeted genes or drugs into the tissues or cells of interest.
There are several approaches indicating that inhibition of HDAC protects the heart against 
injury in different cardiovascular-related diseases, including myocardial infarction, myo-
cardial hypertrophy, and diabetic cardiomyopathy. In addition, HDACi also seem to play a 
therapeutic role in other CVDs with vascular remodelling as one of their main manifestations. 
Here, we review the role of HDACs in these diseases one by one in order to better understand 
the context-dependent effects of HDACs in angiogenesis regulation in these diseases.
6.1. Atherosclerosis
Atherosclerosis of the arteries is a main causative pathogenesis of various CVDs including cor-
onary artery disease (CAD), peripheral vascular disease (PVD), and stroke. It is a chronic path-
ological condition of the arteries that is characterised by the accumulation of lipids, chronic 
inflammation, generation of a fibrous cap, proliferation of SMCs, calcification in vascular 
smooth muscle layer, with the resultant loss of elasticity of arteries. In addition, disturbed 
shear stress (the tangential force of the flowing blood on the endothelial surface of the blood 
vessel) contributes to several elements of atherosclerotic disease. As a result of the growth of 
atheroma, the lumen of the artery is gradually narrowed, which changes the local environ-
ment. Activated ECs within the injury lesions produce adhesion molecules [intercellular adhe-
sion molecule (ICAM) and vascular cell adhesion molecule-1 (VCAM-1)], chemotactic proteins 
[monocyte chemotactic protein-1 (MCP-1)], E- and P-selectin, and growth factors [macrophage 
colony-stimulating factor (M-CSF)] that create a pro-inflammatory environment. The inflam-
matory molecules then recruit monocytes to the vessel wall and promote their transmigration 
across the endothelial monolayer into the intima, where they proliferate, differentiate into 
macrophages, and foam cells by taking up the lipoproteins, leading to neointimal formation. 
With time, the foam cells and macrophages die and release lipid-filled contents and tissue fac-
tors, contributing to the formation of the lipid-rich necrotic core, which is a key component 
of unstable plaques. Meanwhile, SMCs migrate from the medial layer and accumulate within 
the intima, where they synthesise and secrete interstitial collagen and elastin and form the 
fibrous cap over the lesion. Ultimately, the thin fibrous caps rupture, then expose, and release 
procoagulant materials into the blood, triggering the thrombosis that impedes blood flow and 
results in acute stenosis of the arteries, leading to clinical manifestations [49–51].
Because many patients are not candidates for the standard treatments such as angioplasty 
or bypass surgery, a great enthusiasm has emerged for the utilisation of angiogenesis as a 
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 therapeutic modality for atherosclerotic arterial disease. It must be taken into account that 
angiogenesis plays a vital part in the pathogenesis and treatment of CVDs and has become 
one of the hotspots that are being discussed in the past decades. Therapeutic angiogenesis 
provides a valuable tool for treating cardiovascular diseases by stimulating the growth of new 
blood vessels from pre-existing vessels.
This avenue needs to be explored with caution however, as the role of angiogenesis in athero-
sclerosis remains a very contentious topic, and currently, there is no consensus as to whether 
angiogenesis is a way to treat coronary heart disease or in fact is a key causative factor in 
the pathogenesis of atherosclerotic plaque formation. The controversy surrounding the role 
of angiogenesis in ischemic heart disease reflects, in part, the complexity of the underlying 
disease process. There are lot of studies supporting the therapeutic role of angiogenesis in 
atherosclerosis since a key therapeutic objective has been to use the angiogenic cytokines such 
as VEGF or FGF to stimulate collateral blood vessel formation in the ischemic heart and limb 
[52]. But, on the other hand, the pathogenic role of angiogenesis has been suggested as VEGF, 
and other angiogenic growth factors can promote atherosclerosis in certain animal models 
and potentially destabilise coronary plaques by promoting intralesion angiogenesis [53].
Apolipoprotein E-deficient (ApoE−/−) mice, created by homologous recombination in ES cells, was 
first described in 1992 [54, 55]. Since then, this model becomes the most commonly used mouse 
model of atherosclerosis that is able to develop severe hypercholesterolemia and lesions of ath-
erosclerosis highly similar to those observed in humans. Endogenous SIRT1 has been shown to 
decrease macrophage foam cell formation and atherogenesis in ApoE−/−mice [56], while endothe-
lial-specific overexpression of human SIRT1 reduces atherogenesis in ApoE−/− mice and improves 
vascular function [57]. So, in the vasculature, SIRT1 gain-of-function using SIRT1 overexpression 
has been shown to improve endothelial function in mice. Subsequently, it was described that 
SIRT1 does not directly influence endothelium-dependent vascular function in ApoE−/− mice, 
but it improves vascular function by preventing superoxide production in ECs and reduces the 
expression of inflammatory adhesion molecules by suppressing NF-κB signalling [58].
HDACi TSA has been shown to exert contradictory role in the formation of atherosclerotic 
lesion. TSA successfully prevents neointima formation after injury [59, 60]. In contrast, how-
ever, several reports have elucidated the proatherogenic effects of TSA [61]. Another example 
of the discrepancies in TSA roles is the reduction of angiogenesis through the decrease of 
NO level (a key second messenger in angiogenesis signalling) through downregulation of 
eNOS [62]. These contrasting findings reinforce the theory of the contesting role angiogen-
esis plays in atherosclerosis. In addition, it was reported that TSA can reduce the cholesterol 
biosynthesis by repressing the genes involved in the cholesterol, fatty acids, and glycolysis 
pathways [63]. These evidences suggest that TSA could be used as a potential therapeutic 
agent for the control of cholesterol levels as high cholesterol level is one of the main triggers 
of atherosclerosis.
6.2. Myocardial infarction
Myocardial infarction (MI) occurs when blood flow stops to part of the heart causing damage 
to the cardiomyocytes. In physiological conditions, oxygen and nutrients are supplied to the 
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ventricular myocytes by the coronary arteries. Under pathological condition, the coronary 
artery is often occluded by various pathological condition such as the growth of atheroma 
in the coronary artery, rupture of vulnerable plaque, thrombi from proximal lesions, emboli 
secondary to atrial fibrillation, or vegetation after endocarditis.
Several gene or protein therapies to deliver angiogenic factors such as VEGF, FGF2, or FGF4, 
as well as cell therapy using endothelial progenitor cells (EPCs), mesenchymal stem cells 
(MSCs), or induced pluripotent stem cells (iPSCs), have been developed as potential pro-
angiogenic therapeutics for ischemic heart disease and peripheral vascular disease [64, 65]. 
HDAC4 inhibition has been demonstrated to promote cardiac stem cells mediated cardiac 
regeneration and improve the restoration of cardiac function in mice [4]. Granger et al. 
observed that ischemia induces HDAC activity in the heart resulting in increased deacetylation 
of histones H3/4 in vitro and in vivo that leads to injured cardiomyocytes [66]. Furthermore, 
HDACi exert direct antifibrotic activities that alter the response to ischemic cardiac injury and 
reduce infarct size, which are accompanied by improvement in cardiac functions in the mouse 
infarcted heart. However, it is unclear whether these therapeutic effects have any links with 
angiogenesis in these earlier studies.
TSA have exerted an increased angiogenic response in vivo in the mouse infarcted hearts. 
This indicates that TSA preserves cardiac performance and mitigates myocardial remodelling 
through stimulating cardiac endogenous regeneration that could be dependent on enhanced 
angiogenesis within the infarcted heart tissues [67]. The repression of ischemia-induced gene 
expression such as HIF-1α and VEGF has been suggested as possible mechanisms mediated 
by HDACi to stabilise vascular permeability [66]. Recruitment of stem cells has also been sug-
gested as another main mechanism that TSA mediates through. After 8 weeks of TSA treat-
ment in MI mice with or without c-kit deficiency, significantly improved neovascularisation 
and cardiac repair accompanied by cardiac functions and reduced cardiac remodelling can be 
observed in the wildtype infarcted heart compared to the c-kit-deficient mice [68]. It is also 
important to distinguish between the timing of the HDACi effects. Many reports show that 
long-term (8 weeks) administration of HDACi induces neovascularisation [67], while acute 
treatments (12 h) with HDACi inhibit angiogenesis [66].
6.3. Cardiac hypertrophy
Cardiac hypertrophy is a form of remodelling and is an adaptive response to the request for 
high workload from peripheral tissue or from intrinsic underlying disease conditions such as 
valvular dysfunction, hypertension, and MI. The heart responds to stresses by undergoing a 
remodelling process that is associated with myocyte hypertrophy, myocyte death, inflamma-
tion, and fibrosis, which often result in impaired cardiac function and heart failure. These are 
accompanied by activation of the myocyte enhancer factor-2 (MEF2) transcription factor and 
reprogramming of cardiac gene expression. Recent studies have revealed key roles for HDACs 
as both positive and negative regulators of pathological cardiac remodelling (Figure 2).
Members of MEF2 transcription factors family are some of the key regulators of myocardial 
hypertrophy. The first connection between HDACs and the regulation of pathological cardiac 
remodelling was provided by the discovery that class IIa HDACs interact with members of 
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MEF2 transcription factor family [69]. The transcriptional activity of MEF2 factors is upregu-
lated in response to pathological stress in the heart, and ectopic overexpression of constitu-
tively active forms of MEF2 in mouse heart causes dilated cardiomyopathy. It was reported 
that class II HDACs are substrates for a stress-responsive kinase specific for conserved serines 
that regulate MEF2-HDAC interactions. Those kinases phosphorylate the signal-responsive 
sites in class II HDACs, and mutant proteins lacking these phosphorylation sites can act as 
signal-resistant repressors of cardiomyocyte hypertrophy and fetal cardiac gene expression 
in vitro [70]. These studies support a role for class IIa HDACs as endogenous repressors of 
cardiac hypertrophy. Conversely, the function of class IIb HDACs in the heart remains largely 
unknown in heart hypertrophy.
Nevertheless, administration of HDACi TSA 2 weeks after the induction of pressure over-
load can reverse cardiac hypertrophy in mice [71]. The class I selective HDACi MPT0E014 
also improves cardiac contractibility and attenuates structural remodelling in isoproterenol-
induced dilated cardiomyopathy [72]. As there is an intrinsic relationship between decreased 
Figure 2. HDACs in cardiovascular disease. Different risk factors lead to the appearance of atheromatous plaques in the 
coronary arteries, and from these, other cardiovascular diseases such as myocardial infarction occur. The discovery that 
different HDAC enzymes are involved in processes such as angiogenesis has led to the development of inhibitors to 
modulate its effect as a therapeutic treatment ( means induction; ⟞ means inhibition).
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capillary density and the transition of cardiac hypertrophy to cardiac failure [73], it remains 
to be investigated whether the cardioprotective effects exerted by HDACi are related to 
increased angiogenesis within the hypertrophic heart.
6.4. Peripheral artery disease
Peripheral artery disease (PAD) can be defined as the narrowing of the peripheral arteries that 
are not directly linked to the supply to the heart or the brain. PAD development is a multifac-
torial process with many different forms [74].
Different action mechanisms have been proposed for different HDACi in terms of regulating 
angiogenesis in the case of vascular diseases. It was reported in a mouse model of hindlimb 
ischaemia that the inhibition of class IIa HDACs is pro-angiogenic while class I HDAC inhibi-
tion is anti-angiogenic in mouse models of hindlimb ischemia [75].
6.5. Stroke
Stroke is a devastating illness and the second cause of death and disability worldwide after 
cardiac ischemia. A stroke occurs when a blood vessel that carries oxygen and nutrients to 
the brain is either blocked by a clot or bursts. As a consequence, part of the brain can die. 
Post-mortem studies have revealed that angiogenesis can be observed several days after cere-
bral ischemic stroke; it is noteworthy that higher microvessel density correlates with longer 
patient survival [76]. Enhanced angiogenesis facilities neurovascular remodelling processes 
and promotes brain functional recovery after stroke.
There are several studies testing the effects of HDACi in neurovascular remodelling pro-
cesses and in brain functional recovery after stroke. Sun et al. showed that VPA treatment 
enhanced post-ischemic angiogenesis by increasing microvessel density, facilitating EC 
proliferation, and up-regulating rate of cerebral blood flow in the ipsilateral cortex. These 
events may be associated with up-regulation of HIF-1α and its downstream proangiogenic 
target VEGF as well as extracellular MMP2/9 [77]. Similar results were obtained by treating 
rats with VPA during permanent middle cerebral artery occlusion (pMCAO). They exhibit 
reduced infarct volume, promote functional recovery, enhance angiogenesis by upregulat-
ing VEGF [78], and reduce monocytes infiltration [79]. SIRT1 is proangiogenic and increases 
EC tube formation, especially in post-natal angiogenesis [46]. So loss of SIRT1 reduces 
angiogenesis and increases brain infarction, while SIRT1 was also demonstrated to play an 
important role in neuroprotection against brain ischemia by deacetylation and subsequent 
inhibition of p53-induced and nuclear factor κB-induced inflammatory and apoptotic path-
ways [80].
After pMCAO, sodium butyrate and TSA induce neurogenesis via HDACi in multiple isch-
emic brain regions in rats. Sodium butyrate also strongly upregulated VEGF, increasing 
angiogenesis and functional recovery after stroke. It was also described that sodium butyrate 
exhibits neuroprotective/neurogenic effects in rat model of neonatal hypoxia-ischemia [81]. 
All these results highlight that the inhibition of HDAC in brain after stroke enhances angio-
genesis, and this may contribute to the long-term functional recovery after stroke.
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6.6. HDACs role in angiogenesis in diabetes
Diabetes mellitus is a chronic disease where the lack of insulin leads to anomalies in the sub-
strate metabolism, causing a range of acute and long-term complications. One of the main 
complication is the loss of small blood vessels. Another related secondary disease is diabetic 
glomerulomegaly or kidney disease. One of the predominant feature of diabetic glomeru-
lomegaly is an increase in glomerular capillary volume [82], which can be controlled by 
anti-angiogenic therapies. As there is evidence of genetic association between diabetes and 
HDACs, treatment with HDACi exerts a reduction in glomerular endothelial markers expres-
sion, which demonstrates the anti-angiogenic benefit [83]. This effect seems to be opposite 
when it applies to the diabetic heart failure model, as another HDACi sodium butyrate exerts 
improved cardiac functions and increased microvessel density within the diabetic myo-
cardium [84]. Moreover, HDACi also modulates cardiac peroxisome proliferator-activated 
receptors (PPARs) and fatty acid metabolism in diabetic cardiomyopathy [85].
7. Pathogenic role of angiogenesis
7.1. Cancer
There are more than 200 different kinds of cancers, and each type behaves and responds to 
treatments in different ways. Epigenetic enzymes are dysregulated in tumours through muta-
tion or altered expression. More importantly, tumourigenesis is largely due to overexpression 
of oncogenes or the loss of function of tumour suppressor genes. The identification of these 
proteins has driven the rapid development of small-molecule inhibitors.
As we mention above, the function of HDACs is not solely on modifying histones, but they can 
also target many different cellular substrates and proteins, including those that are involved 
in tumour progression. Currently, many HDACi are in clinical trials for cancer therapeutics 
as HDACi result in hyperacetylation (and therefore repression) of genes related to tumour 
cell apoptosis, growth arrest, senescence, differentiation, cell invasion, and metastasis [86].
An exemplary role of HDACi play in modulating the tumour cells directly is its action on 
vasculogenic mimicry (VM). VM refers to the process by which highly aggressive tumour 
cells mimic ECs to form vessel-like structures that aid in supplying enough nutrients to rap-
idly growing tumours [87]. HDAC3 has demonstrated an important facilitative role on VM 
in gliomas, as HDAC3 expression is directly correlated with the number of VM in tumours 
with worsen tumour grade [88]. HDACi such as SAHA exert significant anti-VM effect in the 
progressive pancreatic cancer cells through its inhibition of AKT and ERK signalling path-
ways [89].
The role of HDACs play in tumour angiogenesis has also been studied. It is widely known 
that hypoxia induces tumour angiogenesis and cell survival through the up-regulation of 
VEGF expression in tumour cells [90]. Different studies have reported that inhibition of 
HDAC activity by TSA blocks hypoxia-induced tumour angiogenesis [91]. Other HDACi also 
exert similar effects, as exemplified by MPT0G157, a potent inhibitor of HDAC1, 2, 3, and 6, 
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which was found to promote HIF-1α degradation followed by the downregulation of VEGF 
expression [92]. There are also reports of the anti-tumoural effects of other HDACi (TSA, 
sodium butyrate, and VPA) that are also partly mediated by the reduction of VEGFR-2 expres-
sion that might be related to repressing tumour angiogenesis [93].
SIRT1, a class III HDAC, also plays an important role in tumour initiation, progression, and 
development of drug resistance by hindering senescence, stress-induced apoptosis [94, 95], 
and activating cell growth and angiogenesis. MiR-34a, whose expression level was found to be 
reduced in various tumour cell lines [96, 97], was reported to exert its tumour suppression effect 
via direct binding onto SIRT1 mRNA and regulate cell apoptosis via SIRT1-p53 pathway [98]. 
miR-34a also exerts its anti-tumoural effect through inhibiting SIRT1 to induce the senescence 
of EPCs to suppress EPC-mediated tumour angiogenesis [99].
There are emerging HDACi for cancer therapy. HDACi-targeting class I, II, and IV HDACs to be 
used as anticancer agents are currently under development. One of them, vorinostat, has been 
approved by FDA for treating cutaneous T-cell lymphoma for patients with persistent or recur-
rent disease or following two systemic therapies. Other inhibitors, for example, FK228, PXD101, 
PCI-24781, ITF2357, MGCD0103, MS-275, valproic acid, and LBH589 have also demonstrated 
therapeutic potential as monotherapy or combination with other anti-tumour drugs [86, 100].
7.2. Age-related macular degeneration
Age-related macular degeneration (AMD) is the leading cause of blindness worldwide. 
AMD is characterised by the deposition of drusen aggregates under the retinal epithelium. 
Clusterin is one of the major proteins in drusens [101], and during aging, the expression of 
clusterin increases [102]. The impact of epigenetic modifications on the pathogenesis of AMD 
has been reported. It is known that aging affects histone acetylation status, so it is reasonable 
to presume that the epigenetic regulation might have a role in clusterin expression. It was 
reported that the treatment with HDACi induces prominent increases in the expression levels 
of clusterin mRNA and the secretion of clusterin protein. This result indicates that epigenetic 
factors regulate clusterin expression which could be affecting the pathogenesis of AMD via 
the inhibition of angiogenesis and inflammation [103].
7.3. Pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a condition characterised by increased pulmonary 
vascular resistance and pulmonary artery pressure leading to right heart failure and prema-
ture death [104]. During the process, there is a vascular remodelling caused by dysregulated 
cell proliferation, migration, and survival. The cause of PAH is complex, but the excessive 
proliferation of SMCs and ECs within the pulmonary artery is thought to play an essential 
role in its pathogenesis.
Elevated levels of HDAC1 and HDAC5 have been observed in the PAH lungs, and treatments 
with HDACi such as SAHA and VPA reduce disease worsening in rat models of pulmonary 
hypertension [105]. In addition, MEF2 might have a protective role in PAH progression as 
the expression of MEF2 and its transcriptional targets are significantly decreased in pulmo-
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nary artery ECs from patients with PAH. The impaired MEF2 activity in ECs from PAH was 
associated with increased nuclear accumulation of HDAC4 and HDAC5. So, increasing MEF2 
activity by the selective inhibition of class IIa HDACs by MC1568 seems to suppress exces-
sive EC migration and proliferation by PAH-ECs and can rescue experimental PAH model 
[106]. Although the increased migration and proliferation of pulmonary artery ECs in PAH 
are also hallmarks of angiogenesis, it is still contentious to link excessive angiogenesis with 
the pathogenesis of PAH [107], and any potential anti-angiogenic therapy for PAH should be 
proceeded with caution.
8. Concluding remarks and future perspectives
The past 15 years of research have significantly advanced our understanding of the functions 
and modes of regulation of HDACs in CVD. With all the studies discussed above, we can get 
an idea about how complex it is to translate HDACi as clinical therapeutics as they exert con-
tradictory functions in many occasions. Extensive evidence for HDAC involvement in multi-
protein complexes and cell-specific signalling indicates that a deeper understanding of these 
pathways will be crucial to effective pharmacological targeting in future.
Although angiogenesis seems to be a very promising therapeutic possibility for the majority 
of CVDs where patients are not responding to conventional treatments, there are also times 
that angiogenesis participates in the pathological processes. So in some diseases such as MI 
and diabetic cardiomyopathy, enhancement of angiogenesis is beneficial by improving recov-
ery of injured myocardium. In the other circumstances where aberrant neoangiogensis is one 
of the main disease manifestations (such as cancer and AMD), potentiation of anti-angiogenic 
signalling could be beneficial. Thus, the crucial role that angiogenesis can play as a therapy 
can only be achieved by thoroughly understanding the underlying mechanisms.
In addition, the diverse and contrasting effects that the current available HDACi exert might 
be due to their low specificity to a particular HDAC. Class IIa HDACs are expressed in limited 
organs such as the muscles, brain, or bone, whereas class I HDACs exist ubiquitously. Thus, 
one may question the specificity and adverse effects of unspecific HDACi for therapeutic 
uses. Therefore in the future, creation of more specific HDACi, armed with better understand-
ing of the underlying mechanisms of specific HDAC in angiogenesis within each pathological 
condition, could help the development of more targetted treatments to improve vascularisa-
tion and tissue repairs with higher efficiency and efficacy.
Alternative methods where HDAC modulation can be utilised in therapeutic angiogenesis 
are to modulate endothelial differentiation of stem or progenitor cells, which can be applied 
as cell therapy to enhance angiogenesis within the ischemic tissues. Next-generation gene-
editing tool, such as CRISPR-Cas9, can also be extremely useful in accurately targetting spe-
cific gene responsible for suppressing or exacerbating angiogenesis depending on the diseases. 
Moreover, with diseases such as PAH that are characterised by both lack of angiogenesis 
(within the right ventricles) and excessive angiogenesis (within the pulmonary vasculature), 
the  development of nanoparticles to deliver drugs to specific target tissues can be highly ben-
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eficial. This approach will also be extremely useful for patients that manifest both CVD and 
cancer.
We are currently in an exciting era for translational research with a lot of new inspiring tech-
nologies that can truly transform therapeutic approaches. With diligent efforts to devise the 
role of HDACs underlying angiogenesis robustly in various CVDs, in conjunction with the 
creation of more selective HDAC inhibitors, advanced engineering solutions, and gene-edit-
ing tools to correct genes responsible for repressing angiogenesis, and a commitment in rigor-
ous placebo-controlled clinical trials, superior therapies for CVDs are on the horizon.
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